SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

December 29, 2023

https://www.globenewswire.com/news-release/2023/12/28/2801704/0/en/SeaStar-Medical-Updates-Subject-Enrollment-in-its-Pivotal-Trial-with-the-Selective-Cytopheretic-Device-in-Adults-with-Acute-Kidney-Injury.html

DENVER, Dec. 28, 2023 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces enrollment of 12 subjects in the NEUTRALIZE-AKI pivotal clinical trial evaluating the safety and efficacy of its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).

Read more at globenewswire.com

Related news for (ICU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.